Observational studyMolecular medicine (Cambridge, Mass.)2025
Calpain inhibition as a novel therapeutic strategy for aortic dissection with acute lower extremity ischemia.
Observational study in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Correction: Calpain inhibition as a novel therapeutic strategy for aortic dissection with acute lower extremity ischemia.Molecular medicine (Cambridge, Mass.) · 2026Article
- Molecular Mechanisms and Targeted Intervention Strategies of Calcium Overload in Ischemic Stroke.International journal of molecular sciences · 2026Review
- Immune Determinants of MASLD Progression: From Immunometabolic Reprogramming to Fibrotic Transformation.Biology · 2026Review
- Altered Expression of Calpastatin by Hypoxia Regulates Trophoblast Cell Function through Mitochondria Associated Endoplasmic Reticulum Membranes.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
Abstract
backgroundAortic dissection (AD) patients with malperfusion present significant challenges and are associated with high postoperative mortality rates. Limited data exist regarding the management of patients with AD and acute lower extremity ischemia. Early diagnosis of the extent of malperfusion and timely intervention are critical for improving patient prognosis.
methodsA total of 104 patients diagnosed with AD were enrolled in this observational retrospective study, of which 11 (10.6%) presented with lower limb ischemia (LLI). A comparative analysis was conducted on the clinical data of the AD group and the AD + LLI group. Plasma concentrations of SBDP145, a specific indicator of Calpain activity, were quantified in Control, AD, and AD + LLI groups using ELISA. To explore the role of Calpain in LLI and AD, pharmacological inhibition with Calpeptin and transgenic mice overexpressing calpastatin (Tg-CAST) were utilized in mouse models. RNA sequencing and functional assays were employed to identify the downstream effectors of Calpain.
resultsPatients in the AD + LLI group exhibited significantly elevated leukocyte counts, percentages of neutrophils and lymphocytes, as well as increased serum levels of AST, creatinine, total cholesterol, low-density lipoprotein, uric acid, and creatine kinase compared to those in the AD group. Furthermore, the mean calcium ion concentration and Ca
conclusionsInhibition of Calpain has been demonstrated to decrease the incidence of AD and enhance the restoration of blood flow perfusion in ischemic lower extremities. This effect may be mediated by the upregulation of Fabp3. These findings highlight the potential for targeted interventions against Calpain as a novel therapeutic strategy in the treatment of cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.